Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer

Clin Genitourin Cancer. 2017 Feb;15(1):e65-e68. doi: 10.1016/j.clgc.2016.09.002. Epub 2016 Sep 19.
No abstract available

Keywords: Immunohistochemistry (IHC); Metastatic prostate cancer; Neuroendocrine prostate cancer; Positron emission tomography/computed tomography (PET/CT) imaging; Prostate-specific membrane antigen.

Publication types

  • Case Reports
  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aged
  • Antigens, Surface / metabolism*
  • Carcinoma, Neuroendocrine / diagnostic imaging*
  • Carcinoma, Neuroendocrine / genetics
  • Carcinoma, Neuroendocrine / metabolism
  • Glutamate Carboxypeptidase II / metabolism*
  • Humans
  • Lysine / administration & dosage
  • Lysine / analogs & derivatives*
  • Lysine / pharmacology
  • Male
  • Molecular Imaging
  • Mutation
  • Positron Emission Tomography Computed Tomography
  • Prostatic Neoplasms / diagnostic imaging*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • Retinoblastoma Binding Proteins / genetics
  • Tumor Suppressor Protein p53 / genetics
  • Ubiquitin-Protein Ligases / genetics
  • Urea / administration & dosage
  • Urea / analogs & derivatives*
  • Urea / pharmacology

Substances

  • 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
  • Antigens, Surface
  • RB1 protein, human
  • Retinoblastoma Binding Proteins
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Urea
  • Ubiquitin-Protein Ligases
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II
  • Lysine